Cizzle Biotechnology MOU to take diagnostic capabilities into the therapeutic arena (Interview)

Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the signing of an MOU with St George Street Capital. Allan explains what a companion diagnostic is, what St George Street Capital do, what the proposed commercial agreement will cover and what Cizzle Biotech is looking to achieve over the coming months.

Cizzle Biotechnology is a UK based developer of A blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading  Cizzle Biotechnology expands in the USA with new collaboration agreements

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Cizzle Biotechnology
Cizzle Biotechnology MOU to take diagnostic capabilities into the therapeutic arena (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions